Protease inhibitor monotherapy
I Pérez-Valero, JR Arribas - Current opinion in infectious diseases, 2011 - journals.lww.com
I Pérez-Valero, JR Arribas
Current opinion in infectious diseases, 2011•journals.lww.comThere currently is no consensus about the role of boosted protease inhibitor monotherapy
for the treatment of HIV infection. It is clear that suppression can be maintained in a large
proportion of patients without exposing patients to a substantial risk of resistance
development, but the precise role of this strategy is still undefined.
for the treatment of HIV infection. It is clear that suppression can be maintained in a large
proportion of patients without exposing patients to a substantial risk of resistance
development, but the precise role of this strategy is still undefined.
Summary
There currently is no consensus about the role of boosted protease inhibitor monotherapy for the treatment of HIV infection. It is clear that suppression can be maintained in a large proportion of patients without exposing patients to a substantial risk of resistance development, but the precise role of this strategy is still undefined.
Lippincott Williams & Wilkins